We are live on ! Find out more
CUE icon

Cue Biopharma
CUE

74 hedge funds and large institutions have $31M invested in Cue Biopharma in 2024 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 18 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

232% more call options, than puts

Call options by funds: $292K | Put options by funds: $88K

0.1% more ownership

Funds ownership: 1.11% → 1.21% (+0.1%)

8% less funds holding

Funds holding: 80 → 74 (-6)

22% less capital invested

Capital invested by funds: $39.7M → $31M (-$8.76M)

33% less repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 27

60% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 10

Holders
74
Holders Change
-6
Holders Change %
-7.5%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
18
Reduced
27
Closed
10
Calls
$292K
Puts
$88K
Net Calls
+$204K
Net Calls Change
-$460K

Top Buyers

Rank Fund Capital Flow
1
BL
Bleichroeder LP
New York
+$2.35M
2
GCP
GSA Capital Partners
United Kingdom
+$459K
3
Renaissance Technologies
Renaissance Technologies
New York
+$439K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$354K
5
SPC
Sigma Planning Corp
Michigan
+$346K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$422K
2
CC
Carlson Capital
Texas
-$235K
3
BlackRock
BlackRock
New York
-$223K
4
AC
Annandale Capital
Texas
-$172K
5
Jane Street
Jane Street
New York
-$144K
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
51
Tidal Investments
Wisconsin
$21.9K +$27.3K +387 New
BPA
52
Beacon Pointe Advisors
California
$18.9K – – –
LCGC
53
Legacy Capital Group California
California
$18.9K – – –
Simplex Trading
54
Simplex Trading
Illinois
$18K +$22.4K +318 New
Citigroup
55
Citigroup
New York
$11.5K +$1.13K +16 +9%
GG
56
Gleason Group
Kentucky
$11.3K – – –
Legal & General Group
57
Legal & General Group
United Kingdom
$7.96K – – –
California State Teachers Retirement System (CalSTRS)
58
California State Teachers Retirement System (CalSTRS)
California
$6.84K -$5.36K -76 -39%
TRCT
59
Tower Research Capital (TRC)
New York
$6.18K -$3.81K -54 -33%
NFSG
60
Newbridge Financial Services Group
Florida
$5.67K – – –
Fidelity Investments
61
Fidelity Investments
Massachusetts
$5.56K -$9.1K -129 -57%
AIP
62
Ameritas Investment Partners
Nebraska
$5.39K – – –
Comerica Bank
63
Comerica Bank
Texas
$3.83K +$1.34K +19 +39%
ACA
64
American Capital Advisory
Idaho
$3.57K – – –
Royal Bank of Canada
65
Royal Bank of Canada
Ontario, Canada
$2K -$26.9K -382 -92%
AB
66
Amalgamated Bank
New York
$2K -$8.75K -124 -76%
BHWM
67
Beaird Harris Wealth Management
Texas
$1.51K – – –
Northwestern Mutual Wealth Management
68
Northwestern Mutual Wealth Management
Wisconsin
$945 -$846 -12 -41%
KFS
69
Kelly Financial Services
Massachusetts
$945 – – –
HI
70
Harbour Investments
Wisconsin
$830 – – –
Osaic Holdings
71
Osaic Holdings
Arizona
$718 +$776 +11 +550%
SS
72
Sunbelt Securities
Texas
$448 – – –
AAG
73
Armstrong Advisory Group
Massachusetts
$317 – – –
IA
74
IFP Advisors
Florida
$189 – – –
AWM
75
Avior Wealth Management
Nebraska
$13 – – –
1 2
3
4

CUE Hedge Fund Activity: Q1 2024 in Review

74 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q1 2024, worth a combined $31M — down 22% from $39.7M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of CUE and 4 opened new positions — a net loss of 6 holders — while 27 trimmed existing stakes and 18 added.

The largest buyer was Bleichroeder LP, adding an estimated $2.35M. The largest seller was Morgan Stanley, cutting an estimated $422K.

  • 74 institutional investors held Cue Biopharma (CUE) as of Q1 2024, down from 80 in Q4 2023.
  • Funds reported $31M of Cue Biopharma stock for Q1 2024, down 22% quarter-over-quarter.
  • 4 funds opened new Cue Biopharma positions in Q1 2024 and 10 closed out, a net change of -6 holders.
  • The largest Cue Biopharma buyer in Q1 2024 was Bleichroeder LP, an estimated $2.35M added.
  • The largest Cue Biopharma seller in Q1 2024 was Morgan Stanley, an estimated $422K sold.

Based on aggregated 13F filings for Q1 2024.